# Study of XIAP Antisense for Advanced Cancers

> **NCT00385775** · PHASE1 · TERMINATED · sponsor: **Aegera Therapeutics** · enrollment: 30 (estimated)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** AEG35156

## Key facts

- **NCT ID:** NCT00385775
- **Lead sponsor:** Aegera Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-06
- **Primary completion:** 2008-10
- **Final completion:** 2008-11
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** Dosing cohort (650mg) exceeded current 350mg dosing in other trials.
- **Last updated:** 2008-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00385775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00385775, "Study of XIAP Antisense for Advanced Cancers". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00385775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*